Interim report January – March 2026

The company reported first-quarter net sales of 13.1 MSEK, down 8% from 14.2 MSEK, while operating loss narrowed to -6.3 MSEK from -10.2 MSEK and net loss improved to -6.2 MSEK from -13.3 MSEK. EPS was -0.08 SEK versus -0.35 SEK a year earlier, but operating cash flow remained negative at -3.6 MSEK. The update also notes an extraordinary general meeting on January 9 related to a rights issue, indicating ongoing balance-sheet or financing actions.

Analysis

The operating profile still looks like a business in transition rather than one with self-sustaining demand momentum. The key second-order issue is not the modest improvement in reported losses, but the continued gap between accounting stabilization and cash generation: if working capital remains a drain, a balance-sheet solution will matter more than near-term earnings optics. The rights issue signals management is buying time, but it also raises the probability that incremental upside accrues to the financing structure first, not the equity.

For competitors, a weak standalone cash profile can be an advantage if the company is in a niche where supplier terms, customer retention, or project execution depend on balance-sheet confidence. Counterparties may start preferring better-capitalized rivals, which can create a slow feedback loop: weaker financing terms, less inventory flexibility, and lower bidding capacity. That dynamic tends to show up with a lag of one to three quarters, so the market may still be underpricing the next round of dilution or covenant pressure.

The contrarian angle is that the market may be focusing too much on near-term losses and not enough on the embedded option value of a cleaner capital structure after the rights issue. If the business has any credible path to margin normalization, then the current cash runway could support a sharper rerating than the headline numbers imply. The risk/reward hinges on whether management can convert the financing event into a credible operating reset within the next 6-12 months; otherwise, the equity becomes a serial dilution story.

Key Decisions for Investors

• Avoid initiating outright longs until post-rights-issue dilution is fully absorbed and cash burn stabilizes for at least one quarter; the near-term risk/reward remains skewed to capital loss over operating upside.
• If a liquid short exists, use rallies into financing-related optimism to short the equity or buy puts with a 3-6 month horizon; the catalyst path is further dilution, not immediate earnings recovery.
• For investors willing to speculate on a turnaround, only consider a small starter long after confirmation that operating cash flow improves sequentially for 1-2 quarters and the balance sheet no longer requires emergency funding.
• Pair idea: long a better-capitalized peer in the same end-market against this name to express a relative-quality trade; this captures competitive share shift while reducing sector beta.
• Set a hard risk trigger around any sign of secondary financing or covenant strain within the next 60-90 days, as that would likely override any incremental improvement in reported profitability.